2018-09-26

Seven institutions complete registration for seven stem cell clinical research projects.

Seven institutions complete registration for seven stem cell clinical research projects.

2018-09-21

Centennial Jiuzhitang: Pioneering Global Regenerative Medicine and Embracing China's Stem-Cell Pharmaceutical Era

A major breakthrough has been announced in China's stem-cell therapy field. On September 14, the Jiuzhitang Yonghe Qihang Fund—launched by the century-old traditional Chinese medicine company Jiuzhitang—signed an investment agreement with Stemedica Cell Technologies, a U.S.-based biopharmaceutical firm based in San Diego's renowned "Biotech Valley." Stemedica boasts over a decade of experience in stem-cell research, development, manufacturing, and marketing. Under the agreement, Jiuzhitang Maker (Beijing) Cell Technology Co. will introduce cutting-edge stem-cell production technologies and a state-of-the-art preparation platform from one of the world's leading stem-cell companies. Over the next three to five years, the company plans to build a facility at Beijing’s Daxing Biomedical Industry Base that meets both U.S. and EU c-

2018-09-18

Jiuzhitang Bolsters Regenerative Medicine, Stepping Up Investment in the Stem-Cell Pharmaceutical Sector

On September 14, the Jiuzhitang Yonghe Qihang Fund—established by Jiuzhitang—signed an investment agreement with U.S.-based Stemedica Cell Technologies Inc. (referred to as U.S. Stemedica hereafter), a company located in San Diego's Biotech Valley that boasts over a decade of experience in stem cell research, development, manufacturing, and marketing.

2018-09-18

Chinese medicine companies ramp up R&D in stem cell therapies

Source: China News Service Beijing, September 15 – A traditional Chinese medicine pharmaceutical company recently signed an investment agreement with U.S.-based Cell Technology Inc. in Beijing. The partnership will introduce cutting-edge stem-cell production technology and a state-of-the-art preparation platform from one of the world’s leading stem-cell firms, with plans to build a dedicated stem-cell production facility within 3 to 5 years at the Daxing Biomedical Industry Base in Beijing.

2018-09-18

Jiuzhitang Enters the Stem Cell Pharmaceutical Sector

Source: China Health Media Group – China Food and Drug Network Recently, the Jiuzhitang Yonghe Qihang Fund, established by traditional Chinese medicine pharmaceutical company Jiuzhitang, signed an investment agreement with Stemedica Cell Technology Co., Ltd. (hereafter referred to as Stemedica) in Beijing.

2018-09-18

From "Stem Cell Research" to "Stem Cell Pharmaceuticals" —— The pharmaceutical hub introduces a world-class stem cell production facility.

Source: Zhongguancun Science Park Daxing Biomedical Industry Base Website On September 14, the "Global Stem Cell Industry Development Summit Forum," jointly hosted by the Daxing Biomedical Base and Jiuzhitang Co., Ltd., was successfully held.

2018-09-17

Our province's Youbo Pharmaceutical has taken control of Jiuzhitang, launching its "masterpiece" and becoming the first in China to pioneer "stem-cell-based pharmaceuticals."

Source: Heilongjiang Daily On the 14th, a piece of news that sent ripples through China's pharmaceutical industry was officially announced to the media at the "Global Stem Cell Industry Development Forum": Jiuzhitang Yonghe Qihang Fund, initiated by Jiuzhitang, a well-known domestic traditional Chinese medicine enterprise, has signed an investment agreement with Stemedica Cell Technology, a San Diego-based company from the U.S. Biotech Valley with over a decade of experience in stem cell research, development, production, and marketing. According to the agreement, Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd. will introduce cutting-edge stem cell production technologies and a state-of-the-art preparation platform from a world-leading stem cell firm, aiming to establish these advanced capabilities within 3 to 5 years in northern China.

2018-09-17

Jiuzhitang Introduces International Technology to Enter the Stem-Cell Pharmaceutical Market

Source: Shanghai Securities News On September 14, Jiuzhitang Yonghe Qihang Fund, established by traditional Chinese medicine pharmaceutical company Jiuzhitang, signed an investment agreement with Stemedica Cell Technology Co., Ltd. (referred to as "Stemedica"), a U.S.-based biotechnology firm. According to the agreement, Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd. (referred to as "Jiuzhitang Maker") will introduce cutting-edge stem cell production technologies and a state-of-the-art preparation platform from a world-leading stem cell company, aiming to build a commercial-grade stem cell facility meeting both U.S. and EU cGMP (current Good Manufacturing Practice) standards within three to five years at the Daxing Biomedical Industry Base in Beijing.

2018-09-16

Traditional Chinese medicine company Jiuzhitang introduces international technology to enter the stem cell field.

Source: Sohu.com Recently, the "Global Stem Cell Industry Development Summit Forum," jointly hosted by Jiuzhitang Co., Ltd. and the Daxing Biomedical Industry Base of Zhongguancun Science Park, with co-organization from the Zhongguancun Medical Device Park, was held in Beijing.